Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19

Conditions

• Tuberculosis

Interventions

• COMBINATION_PRODUCT: 13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)
• COMBINATION_PRODUCT: 9 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)
• COMBINATION_PRODUCT: All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)
• COMBINATION_PRODUCT: All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)
• COMBINATION_PRODUCT: 13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)
• OTHER: The standard therapy

Sponsor

Kafrelsheikh University

Collaborators

• [object Object]